June 2025 - BioMedWire (BMW)

FridayJun 20, 2025 10:00 am

How Robotics Technology is Transforming Healthcare

Robotics is playing an ever-increasing role in revolutionizing healthcare. The medical industry is playing a leading role in the adoption of robotics and the pace at which these technologies are being adopted is accelerating. It is therefore not surprising that the market for medical robotics is forecast to grow from $16.6bn to $63.8bn between 2023 and 2032. Several applications of these technologies are justifying further deployment. Speeding up diagnosis Intuitive, a U.S. firm, developed a robotic-assisted system and platform called Ion. This tool and the supporting system is geared at conducting bronchoscopies in a minimally invasive way in order to…

FridayJun 20, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Reimagining Drug Safety Through Scalable Innovation

Nutriband Inc. has been granted a new U.S. patent for its AVERSA(TM) transdermal abuse-deterrent technology, expanding its domestic IP coverage AVERSA(TM) is designed to prevent misuse, abuse, and accidental exposure of transdermal drugs with abuse potential, such as fentanyl With overdose deaths still plaguing the U.S., Nutriband’s platform has the potential to enhance drug safety across multiple therapeutic categories The opioid crisis remains one of the most persistent public health emergencies in the U.S. While state and federal initiatives have helped curb some of the worst-case trajectories, more than 100,000 Americans still die each year from drug overdoses, a significant proportion linked to synthetic…

WednesdayJun 18, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis

Psoriasis affects approximately 3% of the adult population in the United States, translating to more than 7.5 million individuals. By using visible light, Soligenix’s SGX302 aims to mitigate risks while effectively reducing inflammation and promoting skin healing. A phase 2a study demonstrated that SGX302 was well tolerated, with no significant adverse events reported. Psoriasis is more than just a skin condition — it’s a lifelong autoimmune disorder that disrupts daily life with painful, inflamed patches and an emotional toll that can be just as severe as the physical symptoms. Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies…

TuesdayJun 17, 2025 10:00 am

Study Finds the Overall Prevalence of Psoriasis in the US Unchanged

A recently published analysis that appeared in the Journal of American Academy of Dermatology has concluded that the general percentage of adults in the U.S. diagnosed with psoriasis remains unchanged at 3% over the past 10 years. However, the investigators mention several points of concern that aren’t reflected in this general summary. For starters, they point out that the population in America has expanded. Consequently, a stable overall percentage of individuals diagnosed with psoriasis shouldn’t be taken to mean that the caseload has decreased. For example, at the current U.S. population, 3% translates into approximately 8 million individuals, which is…

TuesdayJun 17, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease

Behçet’s disease is more prevalent in countries along the Silk Road, including Türkiye, Iran and Japan. Even with treatment, symptoms can continue occurring for many patients and significantly affect their quality of life and productivity. Soligenix has initiated a clinical trial to evaluate the safety, tolerability and preliminary efficacy of SGX945 in patients suffering from oral ulcers. Behçet’s disease is a rare, chronic autoimmune disorder characterized by inflammation of blood vessels, leading to a range of symptoms including painful mouth and genital ulcers, eye inflammation and skin lesions. With limited treatment options available, Soligenix (NASDAQ: SNGX) is at the forefront of…

MondayJun 16, 2025 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam has developed the first cable-free system capable of synthesizing a 12-lead ECG from 3D, non-coplanar electrical signals captured in real time. Patients can have the HeartBeam System with them at all times, ready to record an ECG in 30 seconds at home or anywhere when they feel symptoms to reduce delays in care. The HeartBeam System is now FDA cleared for arrhythmia assessment, with additional FDA review underway for its 12-lead ECG synthesis software for the same indication. A recent partnership with AccurKardia enhances HeartBeam’s arrhythmia solution with an FDA-cleared automated rhythm interpretation software. HeartBeam holds 20 issued patents,…

FridayJun 13, 2025 10:00 am

New Study Shows TTFields Amplify Immune Attack Against Brain Cancer

Breakthrough research conducted by a team at the University of Southern California (USC) has found that electric fields, administered through a device placed on a patient’s scalp, can supercharge the immune system’s ability to combat glioblastoma and increase the survival time of the patient. These benefits for patients were attained after combining the electric fields with chemotherapy and immunotherapy treatments. Glioblastoma is a brain cancer whose prognosis is very poor because it grows rapidly and the existing treatments usually have a minimum beneficial impact upon the progress of the cancer. On average, patients with this type of brain tumor survive…

ThursdayJun 12, 2025 10:00 am

Study Finds Kids with MS Biologically Age Faster Than Those Without It

New research conducted by UC San Diego researchers has revealed that adolescents and children having multiple sclerosis exhibit accelerated biological ageing. These findings were published in the journal Neurology. This study suggests that the changes linked to ageing could be happening earlier than had initially been thought among patients with MS. MS, a chronic disease affecting the CNS (central nervous system), largely exhibits its effects on the optic nerves, the brain and spinal cord. Most research on this disease has focused on adults, and this UC San Diego study is the first to investigate biological ageing in younger individuals afflicted…

ThursdayJun 12, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Reports Double-Digit Revenue Increase, Continued Progress on AVERSA Fentanyl Development

Financial momentum for Nutriband is indicated by its recent Q1 financial report Progress continues development of proprietary AVERSA(TM) Fentanyl, notes quarterly report AVERSA(TM) Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch A wave of positive developments continues to build momentum for Nutriband (NASDAQ: NTRB), with recent capital funding, strategic partnerships and an expanded intellectual property portfolio reinforcing its bid to lead in the development of safer transdermal therapies. Nutriband is positioning itself at the forefront of abuse-deterrent drug delivery by advancing its Aversa platforms, notably its flagship fentanyl patch and buprenorphine candidates. Financial momentum for Nutriband is…

ThursdayJun 12, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is facing a severe ketamine shortage, prompting NRx to seek priority FDA review. NRX-100 eliminates benzethonium chloride, aligning with U.S. health initiatives to remove toxic preservatives. The company plans to petition the FDA to remove benzethonium chloride from all intravenous ketamine products. The filing complements the company’s NDA for NRX-100 for suicidal depression, with a PDUFA date expected in late 2025. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for NRX-100, a preservative-free formulation…